

Date

Dear Healthcare Professional.

Shortage of ESTRADOT 37.5 estradiol 37.5 microgram transdermal drug delivery system sachet (AUST R: 338057), ESTRADOT 50 estradiol 50 microgram transdermal drug delivery system sachet (AUST R: 338058), ESTRADOT 75 estradiol 75 microgram transdermal drug delivery system sachet (AUST R: 338059), and ESTRADOT 100 estradiol 100 microgram transdermal drug delivery system sachet (AUST R: 338060) and alternate supply arrangement under Section 19A of the *Therapeutic Goods Act 1989*.

## The above Australian registered medicines are in shortage due to manufacturing issues.

Medsurge has been able to arrange for the supply of ESTRAMON estradiol 37.5 microgram/24 hours transdermal patch (Germany), ESTRAMON estradiol 50 microgram/24 hours transdermal patch (Germany), ESTRAMON estradiol 75 microgram/24 hours transdermal patch (Germany) and ESTRAMON estradiol 100 microgram/24 hours transdermal patch as alternative products on a temporary basis. These products are NOT registered in Australia, and supply is authorised under an approval granted by the Therapeutic Goods Administration (TGA) under section 19A of the *Therapeutic Goods Act 1989* until **Date** for the following indication:

Short term treatment of symptoms of estrogen deficiency due to the menopause, whether natural or surgically induced.

In women with an intact uterus, estrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

## Please note: CONTAINS SOYBEAN OIL

The section 19A approved medicines are contraindicated in patients with known hypersensitivity to the active ingredient, soy, peanut or any of the other ingredients listed.

Prior to dispensing and administering, healthcare professionals should determine if this product is suitable for the patient.

ESTRAMON estradiol 37.5 microgram/24 hours transdermal patch (Germany), ESTRAMON estradiol 50 microgram/24 hours transdermal patch (Germany), ESTRAMON estradiol 75 microgram/24 hours transdermal patch (Germany) and ESTRAMON estradiol 100 microgram/24 hours transdermal patch (Germany) are identical in active ingredient and strength to the Australian registered products.





A comparison table between the Australian registered **ESTRADOT estradiol transdermal drug delivery system sachet** and **ESTRAMON estradiol transdermal patch (Germany)** is given below:

	ESTRADOT estradiol transdermal drug delivery system sachet	ESTRAMON estradiol transdermal patch (Germany)
Pack Presentation	Carton of 8 transdermal patches	Carton of 6, 18 or 24 transdermal patches
Excipients	Dipropylene glycol, povidone and oleyl alcohol. Proprietary ingredients: Gelva RA-788 acrylic adhesive, BIO-PSA (R) 7-4502 silicone adhesive, Dow BLF 2550 non-removable backing layer film and Scotchpak 1022 removable release liner.	Matrix: Poly[(2-ethylhexyl)acrylate-co- methylacrylate-co-acrylic acid-co- (2,3-epoxypropyl)methacrylate] (62.2:32.0:5.7:0.03),RRR-alpha- Tocopherol preparation (USP) (contains soybean oil [Ph.Eur.]) Carrier film: Polyethylene terephthalate Protective film: Polyethylene terephthalate, siliconized
Storage	Store below 25°C.	Do not store above 30°C.

Please refer to the Australian Product Information for ESTRADOT 37.5 estradiol 37.5 microgram transdermal drug delivery system sachet (AUST R: 338057), ESTRADOT 50 estradiol 50 microgram transdermal drug delivery system sachet (AUST R: 338058), ESTRADOT 75 estradiol 75 microgram transdermal drug delivery system sachet (AUST R: 338059), and ESTRADOT 100 estradiol 100 microgram transdermal drug delivery system sachet (AUST R: 338060) available here: www.ebs.tga.gov.au when prescribing ESTRAMON estradiol 37.5 microgram/24 hours transdermal patch (Germany), ESTRAMON estradiol 50 microgram/24 hours transdermal patch (Germany) and ESTRAMON estradiol 100 microgram/24 hours transdermal patch (Germany).

Patients should be advised to disregard the German patient leaflet for ESTRAMON estradiol 37.5 microgram/24 hours transdermal patch (Germany), ESTRAMON estradiol 50 microgram/24 hours transdermal patch (Germany). ESTRAMON estradiol 75 microgram/24 hours transdermal patch (Germany) and ESTRAMON estradiol 100 microgram/24 hours transdermal patch (Germany) contained within the pack and refer to the English-translated leaflet provided with the medicine for application instructions.

Any adverse events which are experienced with ESTRAMON estradiol 37.5 microgram/24 hours transdermal patch (Germany), ESTRAMON estradiol 50 microgram/24 hours transdermal patch (Germany), ESTRAMON estradiol 75 microgram/24 hours transdermal patch (Germany) and ESTRAMON estradiol 100 microgram/24 hours transdermal patch (Germany) should be reported by healthcare professionals and patients to Medsurge on 1300 788 261 or email sales@medsurge.com.au. Alternatively, this information can be reported to the TGA at https://www.tga.gov.au/reporting-problems.

Any product complaints with ESTRAMON estradiol 37.5 microgram/24 hours transdermal patch (Germany), ESTRAMON estradiol 50 microgram/24 hours transdermal patch (Germany), ESTRAMON estradiol 75 microgram/24 hours transdermal patch (Germany) and ESTRAMON estradiol 100 microgram/24 hours transdermal patch (Germany) should be reported to Medsurge on 1300 788 261 or email sales@medsurge.com.au.

Please forward this information to relevant staff members in your organisation.



## medsurge

For	further	information,	please	contact	Medsurge	Healthcare	on	1300	788	261	or	at	email
sales@medsurge.com.au.													

Kind regards,

Senior Regulatory Officer

Medsurge Healthcare

